Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer

NCT00056407 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00056407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2003
Completion date
April 30, 2009
Enrollment
8,231 (actual)
Sites
932

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, prostate